Our News section keeps you up to speed with the latest developments at Cytel.
- Cytel is one of the leading global providers of clinical trial design technology, biometric services and advanced analytics, focusing on optimizing clinical trials and helping pharmaceutical companies to unlock the full potential of their clinical and real-world data
- Nordic Capital and Astorg will actively support and accelerate Cytel’s next phase of growth and innovation, drawing on their extensive experience of investing in healthcare and technology
New Acquisition Further Expands Cytel’s Global Consultancy in Health Economics Outcomes Research and Value Communications
Waltham, MA, October 6, 2020 – Cytel Inc. has launched SolaraTM, a collaborative decision-support platform that revolutionizes the identification of optimal clinical trial designs for greater business results for biotech and pharmaceutical companies.
Two South Africa sites added to TOGETHER platform trials for the outpatient treatment of high-risk adults infected with SARS-CoV-2
Cytel Inc. has significantly widened the geographical scope of the TOGETHER trial, a unique study to identify early COVID-19 interventions in underserved low- and middle-income country (LMIC) populations. The trial, supported with seed funding from the Bill & Melinda Gates Foundation, is one of the very few studies investigating therapies at the earliest stages of COVID-19 infection, and is the only trial to explore early interventions in the Global South. The expansion consists of two new sites in South Africa to complement the study sites actively recruiting in Brazil and the United States. By leveraging its expertise in such complex trial designs, Cytel’s Global Health team is making a lasting contribution to local trial infrastructure to support future clinical investigation in these vulnerable populations.
Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. The acquisition further builds Cytel’s dedicated team of Bayesian experts to include several new and highly esteemed biostatisticians led by renowned Bayesian design specialist Dr. Yuan Ji, who also jointly holds an appointment as Professor of Biostastistics at the University of Chicago. The deal follows the recent release of Cytel’s East Alloy platform for easy access to verified Bayesian tools, and marks the latest step in Cytel’s commitment to broadening industry access to the most innovative clinical trial design methods.
Cytel Inc., an advanced
Global COVID-19 Clinical Trial Tracker
Cytel Inc. has launched an open-access global COVID-19 Clinical Trial Tracker to help facilitate greater collaboration between researchers, policymakers, clinicians, journalists, philanthropists, and other critical stakeholders who need to understand the complex dynamics of the global response to finding a solution to the COVID-19 outbreak.
Collaboration to accelerate new clinical trial technologies and techniques for disease-focused RWE production
Clinical trial biostatistics and advanced data analytics leader Cytel Inc. joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative as a strategic partner.
Waltham MA, March 04, 2020 — A new paper authored by statistical experts at Cytel has been published in the world-renowned journal CA: A Cancer Journal for Clinicians. The open-access paper, titled ‘An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians,’ provides a valuable resource for increasing master protocol trial literacy among the many clinicians and researchers who may not be familiar with these innovative trial types. Such trials offer considerable potential value in more rapidly bringing new oncology therapeutics to patients. However, there is a critical need for improved understanding in order to optimize their use. To further address this need, Jay Park, Director at Cytel and lead author on the article, will host a free 60-minute webinar on March 19, to expand on the contents of the article, discussing the unique features of umbrella and basket trials and outlining the key considerations for their successful design and implementation.